Preet Chaudhary

Company: Angeles Therapeutics

Job title: Founder

Seminars:

Synthetic Immune Receptor, A Next Generation CAR-T Platform 2:45 pm

Describing the current challenges facing cell therapy Describing the reasons why CAR-T therapies have failed and especially in solid tumors Introducing Synthetic Immune Receptor (SIR), a next generation HLA-independent TCR platform and describing the activity of SIR against solid tumors and blood cancersRead more

day: Post-Conference Solid Tumor Focus Day